Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
暂无分享,去创建一个
R. Bateman | E. McDade | J. Cummings | A. Koyama | C. Swanson | S. Dhadda | L. Reyderman | Michael Irizarry | M. Kanekiyo | Michael C Irizarry | L. Kramer